Live Quote · NASDAQCURXHealthcare· Biotechnology

Curanex Pharmaceuticals Inc Common Stock

$0.25 7.04%($-0.02)
TickerSpark Score
52/100
Mixed
93
Valuation
20
Profitability
15
Growth
100
Health
30
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CURX research report →

52-Week Range0% of range
Low
$0.25
Current
$0.25
High
$9.18
Company Overviewwww.curanexpharma.com

About the company

Curanex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused on identifying, advancing, and bringing to market plant-based medicines to address various inflammatory conditions. Their primary drug candidate, Phyto-N, is currently in development for a broad spectrum of health issues, including but not limited to ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne.

CEO
Jun Liu
IPO
2025
Employees
6
HQ
Jericho, NY, US

Price Chart

-93.66% · this period
$9.16$4.71$0.25Aug 26Jan 29Jul 02
Valuation
Market Cap
$7.22M
P/E
-0.94
P/S
0.00
P/B
0.89
EV/EBITDA
-1.19
Div Yield
0.00%
Profitability
Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
-85.41%
ROIC
-86.83%
Growth & Income
Revenue
$0 · 0.00%
Net Income
$-4,225,106 · -1068.75%
EPS
$-0.17 · -1207.69%
Op Income
$-4,239,076
FCF YoY
-1787.14%
Performance & Tape
52W High
$9.18
52W Low
$0.25
50D MA
$0.33
200D MA
$0.50
Beta
-2.85
Avg Volume
98.08K

Get TickerSpark's AI analysis on CURX

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Aug 25, 25Xie Liqinother0
Aug 25, 25Hsu Helen Hongother0
Aug 25, 25Zhong Huijuanother0
Aug 25, 25Yan Yongother0
Aug 25, 25Liu Junother0
Aug 25, 25Liu Junother0
Aug 25, 25Liu Junother0
Aug 25, 25Liu Junother0
Aug 25, 25Liu Junother0
Aug 25, 25Hao Xiaohuiother0
Coverage · CURX

Our CURX coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on CURX yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate CURX report →
Internal Compare

Similar companies

Peers in the same neighborhood.